These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

202 related items for PubMed ID: 10953973

  • 1. Randomized comparison of mobilization kinetics of circulating CD34+ cells between biweekly CHOP and dose-escalated CHOP with the prophylactic use of lenograstim (glycosylated rHuG-CSF) in aggressive non-Hodgkin's lymphoma. The lenograstim/Lymphoma Study Group.
    Itoh K, Ohtsu T, Sasaki Y, Ogura M, Morishima Y, Kasai M, Chou T, Yoshida K, Ohno T, Mizorogi F, Uike N, Sai T, Taniwaki M, Ikeda S, Tobinai K.
    Leuk Lymphoma; 2000 Aug; 38(5-6):521-32. PubMed ID: 10953973
    [Abstract] [Full Text] [Related]

  • 2. Randomized phase II study of biweekly CHOP and dose-escalated CHOP with prophylactic use of lenograstim (glycosylated G-CSF) in aggressive non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9505.
    Itoh K, Ohtsu T, Fukuda H, Sasaki Y, Ogura M, Morishima Y, Chou T, Aikawa K, Uike N, Mizorogi F, Ohno T, Ikeda S, Sai T, Taniwaki M, Kawano F, Niimi M, Hotta T, Shimoyama M, Tobinai K, Members of the lymphoma study group of the Japan Clinical Oncology Group (JCOG).
    Ann Oncol; 2002 Sep; 13(9):1347-55. PubMed ID: 12196359
    [Abstract] [Full Text] [Related]

  • 3. A dose-finding study of glycosylated G-CSF (Lenograstim) combined with CHOP therapy for stem cell mobilization in patients with non-Hodgkin's lymphoma.
    Takeyama K, Ogura M, Morishima Y, Kasai M, Kiyama Y, Ohnishi K, Mitsuya H, Kawano F, Masaki Y, Sasaki T, Chou T, Yokozawa T, Tobinai K, Lenograstim/Lymphoma Study Group.
    Jpn J Clin Oncol; 2003 Feb; 33(2):78-85. PubMed ID: 12629058
    [Abstract] [Full Text] [Related]

  • 4. Mobilization of peripheral blood stem cells by granulocyte-colony stimulating factors: comparison of a standard dose of glycosylated and mutated granulocyte-colony stimulating factor in non-Hodgkin's lymphoma patients following CHOP therapy.
    Takemoto Y, Wada H, Takatsuka H, Okamoto T, Kakishita E.
    Drugs Exp Clin Res; 2000 Feb; 26(1):1-5. PubMed ID: 10761530
    [Abstract] [Full Text] [Related]

  • 5. The effect of the dexamethasone, cytarabine, and cisplatin (DHAP) regimen on stem cell mobilization and transplant outcomes of patients with non-Hodgkin's lymphoma who are candidates for up-front autologous stem cell transplantation.
    Jeon SY, Yhim HY, Kim HS, Kim JA, Yang DH, Kwak JY.
    Korean J Intern Med; 2018 Nov; 33(6):1169-1181. PubMed ID: 29295612
    [Abstract] [Full Text] [Related]

  • 6. Dose-escalation study of CHOP with or without prophylactic G-CSF in aggressive non-Hodgkin's lymphoma.
    Itoh K, Ohtsu T, Wakita H, Igarashi T, Ishizawa K, Onozawa Y, Fujii H, Minami H, Sasaki Y.
    Ann Oncol; 2000 Oct; 11(10):1241-7. PubMed ID: 11106111
    [Abstract] [Full Text] [Related]

  • 7. Mobilization of peripheral blood progenitor cells following CHOP treatment combined with delayed granulocyte colony-stimulating factor administration in patients with non-Hodgkin's lymphoma.
    Takano H, Sawada K, Sato N, Natoya A, Tarumi T, Hirayama S, Koizumi K, Takahashi TA, Sekiguchi S, Koike T.
    Leuk Lymphoma; 1996 May; 21(5-6):473-8. PubMed ID: 9172813
    [Abstract] [Full Text] [Related]

  • 8. A dose-finding study of lenograstim (glycosylated rHuG-CSF) for peripheral blood stem cell mobilization during postoperative adjuvant chemotherapy in patients with breast cancer. Lenograstim/Breast Cancer Study Group.
    Narabayashi M, Takeyama K, Fukutomi T, Tokuda Y, Tajima T, Okumura A, Chou T, Sano M, Makino H, Igarashi T, Sasaki Y, Imoto S, Ogura M, Morishima Y, Murai H, Okamoto S, Ikeda T, Kasai M, Yokozawa T, Tobinai K.
    Jpn J Clin Oncol; 1999 Jun; 29(6):285-90. PubMed ID: 10418556
    [Abstract] [Full Text] [Related]

  • 9. Dose escalation of biweekly cyclophosphamide, doxorubicin, vincristine, and prednisolone using recombinant human granulocyte colony stimulating factor in non-Hodgkin's lymphoma.
    Tanosaki R, Okamoto S, Akatsuka N, Ishida A, Michikawa N, Masuda Y, Uchida H, Murata M, Kizaki M, Ikeda Y.
    Cancer; 1994 Oct 01; 74(7):1939-44. PubMed ID: 7521788
    [Abstract] [Full Text] [Related]

  • 10. High-dose versus low-dose cyclophosphamide in combination with G-CSF for peripheral blood progenitor cell mobilization.
    Ahn JS, Park S, Im SA, Yoon SS, Lee JS, Kim BK, Bang SM, Cho EK, Lee JH, Jung CW, Kim HC, Seong CM, Lee MH, Kim CS, Lee KS, Lee JA, Ahn MJ.
    Korean J Intern Med; 2005 Sep 01; 20(3):224-31. PubMed ID: 16295781
    [Abstract] [Full Text] [Related]

  • 11. Blood progenitor cell (BPC) mobilization studied in multiple myeloma, solid tumor and non-Hodgkin's lymphoma patients after combination chemotherapy and G-CSF.
    Engelhardt M, Winkler J, Waller C, Lange W, Mertelsmann R, Henschler R.
    Bone Marrow Transplant; 1997 Mar 01; 19(6):529-37. PubMed ID: 9181898
    [Abstract] [Full Text] [Related]

  • 12. Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).
    Wunderlich A, Kloess M, Reiser M, Rudolph C, Truemper L, Bittner S, Schmalenberg H, Schmits R, Pfreundschuh M, Loeffler M, German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).
    Ann Oncol; 2003 Jun 01; 14(6):881-93. PubMed ID: 12796026
    [Abstract] [Full Text] [Related]

  • 13. CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma.
    Doorduijn JK, van der Holt B, van Imhoff GW, van der Hem KG, Kramer MH, van Oers MH, Ossenkoppele GJ, Schaafsma MR, Verdonck LF, Verhoef GE, Steijaert MM, Buijt I, Uyl-de Groot CA, van Agthoven M, Mulder AH, Sonneveld P.
    J Clin Oncol; 2003 Aug 15; 21(16):3041-50. PubMed ID: 12915593
    [Abstract] [Full Text] [Related]

  • 14. Chemotherapy dose intensity in non-Hodgkin's lymphoma: is dose intensity an emerging paradigm for better outcomes?
    Gregory SA, Trümper L.
    Ann Oncol; 2005 Sep 15; 16(9):1413-24. PubMed ID: 15932900
    [Abstract] [Full Text] [Related]

  • 15. Low-dose granulocyte colony-stimulating factor overcomes neutropenia in the treatment of non-Hodgkin's lymphoma with higher cost-effectiveness.
    Hara T, Tsurumi H, Kasahara S, Kanemura N, Yoshikawa T, Goto N, Kojima Y, Yamada T, Sawada M, Takahashi T, Oyama M, Tomita E, Moriwaki H.
    Int J Hematol; 2005 Dec 15; 82(5):430-6. PubMed ID: 16533747
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Efficacy of delayed granulocyte colony-stimulating factor after full dose CHOP therapy in non-Hodgkin's lymphoma: a pilot study for a leukocyte count oriented regimen.
    Sawada KI, Sato N, Kohno M, Hannda H, Yasukouchi T, Tanngo M, Hirayama A, Koike T.
    Leuk Lymphoma; 1995 Dec 15; 20(1-2):103-9. PubMed ID: 8750630
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Prospective randomized comparative observation of single- versus split-dose lenograstim to enhance engraftment after autologous stem cell transplantation in patients with multiple myeloma or non-Hodgkin's lymphoma.
    Jang G, Ko OB, Kim S, Lee DH, Huh J, Suh C.
    Transfusion; 2008 Apr 15; 48(4):640-6. PubMed ID: 18194384
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.